Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: Potential involvement of breast cancer resistance protein (ABCG2)

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 8, 2010, Pages 973-984

  Guo, Shiyan ^a   Zhang, Xinxin ^a   Gan, Li ^a   Zhu, Chunliu ^a   Gan, Yong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

biliary excretion; breast cancer resistance protein (BCRP); intestinal toxicity; irinotecan hydrochloride (CPT 11); poly (ethylene oxide) poly (propylene oxide) poly (ethylene oxide) micelles

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; IRINOTECAN; NOVOBIOCIN; PHOSPHATIDYLCHOLINE; POLY(ETHYLENE OXIDE) POLY(PROPYLENE OXIDE) POLY(ETHYLENE OXIDE); POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL TRANSPORT; CELLULAR DISTRIBUTION; CIRCULATION TIME; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TRANSPORT; GASTROINTESTINAL TOXICITY; INHIBITION KINETICS; INTESTINE INJURY; LIVER METABOLISM; MALE; MICELLE; MICROSCOPY; NONHUMAN; RAT; TRANSPORT KINETICS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CAMPTOTHECIN; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DOGS; DRUG CARRIERS; DRUG COMPOUNDING; EPITHELIAL CELLS; INJECTIONS, INTRAVENOUS; INTESTINES; LECITHINS; MALE; MICELLES; NOVOBIOCIN; POLYETHYLENE GLYCOLS; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; TRANSFECTION;

EID: 77954931472     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01128.x     Document Type: Article

References (36)

1. Jaxel C et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase 1: evidence for a specific receptor site and for a relation to antitumour activity. Cancer Res 1989 49 : 1465 1469.
2. Humerickhouse R et al. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000 60 : 1189 1192.
3. Iyer L et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998 101 : 847 854.
4. Ohno R et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990 8 : 1907 1912.
5. Kudoh S et al. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy of cisplatin. Jpn J Cancer Res 1995 86 : 406 413.
6. Negoro S et al. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991 83 : 1164 1168.
7. Takasuna K et al. Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Folia Pharmacol Jpn 1995 105 : 447 460.
8. Gupta E et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994 54 : 3723 3725.
9. Takasuna K et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996 56 : 3752 3757.
10. Alfred HS, Johan WJ. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003 55 : 3 29.
11. Mathijssen RH et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11), Clin. Cancer Res 2001 7 : 2182 2194.
12. Yamamoto W et al. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs 2001 12 : 419 432.
13. Wei Y et al. Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion. Mol Pharm 2009 6 : 134 143.
14. Zhang XX et al. Effect of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs. Acta Pharmacol Sin 2008 29 : 1391 1398.
15. Zhang W et al. Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: Formulation, optimization and in vitro characterization. Int J Pharm 2009 376 : 176 185.
16. Yan G et al. Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin. Colloid Surface B 2008 64 : 194 199.
17. Elena VB, Alexander VK. Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008 130 : 98 106.
18. Alakhov V et al. Block copolymer-based formulation of doxorubicin: from cell screen to clinical trials. Colloid Surface B 1999 16 : 113 134.
19. Jennifer DI et al. MDCK (Madin-Darby Canine Kidney) cells: a tool for membrane permeability screening. J Pharm Sci 1999 88 : 28 33.
20. Liu Y, Zeng S. Advances in the MDCK-MDR1 cell model and its applications to screen drug permeability. Acta Pharm Sin 2008 43 : 559 564.
21. Michalowski CB et al. Microdialysis for evaluating the entrapment and release of a lipophilic drug from nanoparticles. J Pharmceut Biomed 2004 35 : 1093 1100.
22. Yang XX et al. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide. Curr Drug Metab 2006 7 : 431 454.
23. Su YM et al. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. J Pharm Pharm Sci 2007 10 : 519 536.
24. Yamagata T et al. Effect of excipients on breast cancer resistance protein substrate uptake activity. J Control Release 2007 124 : 1 5.
25. Elena B et al. Fundamental Relationships between the composition of Pluronic block copolymer and their hypersensitization effect in MDR cancer cells. Pharm Res 1999 16 : 1373 1379.
26. Burger H et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP) /ABCG2 drug pump. Blood 2004 104 : 2940 2942.
27. Alakhova DY et al. Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. J Control Release 2010 142 : 89 100.
28. Giri N et al. Substrate- dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos 2009 37 : 560 570.
29. Arimori K et al. Effect of P-glycoprotein modulator, cyclosporine A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm. Res 2003 20 : 910 917.
30. Kehrer DFS et al. Modulation of Irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001 7 : 1136 1141.
31. Smith NF et al. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2006 20 : 163 175.
32. Yamagata T et al. Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients. Int J Pharm 2009 370 : 216 219.
33. Kase Y et al. Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn J Pharmacol 1997 75 : 407 413.
34. Burakoff R, Percy WH. Studies in vivo and in vitro on effects of PGE2 on colonic motility in rabbits. Am J Physiol Gastrointest Liver Physiol 1992 262 : 23 29.
35. +-ATPase activity and ouabain binding in MDCK cells. Am J Physiol Renal Physiol 1993 264 : F61 F65.
36. - secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon. Naunyn Schmiedebergs Arch Pharmacol 1995 351 : 309 314.